Eli Lilly and Company (BVMF:LILY34)

Brazil flag Brazil · Delayed Price · Currency is BRL
131.57
-1.03 (-0.78%)
Last updated: Aug 28, 2025, 2:02 PM GMT-3
-0.78%
Market Cap3.59T
Revenue (ttm)290.19B
Net Income (ttm)75.19B
Shares Outn/a
EPS (ttm)83.33
PE Ratio47.71
Forward PE26.13
Dividend0.75 (0.56%)
Ex-Dividend DateAug 14, 2025
Volume10,107
Average Volume29,708
Open132.66
Previous Close132.60
Day's Range131.43 - 133.38
52-Week Range113.00 - 181.98
Beta0.44
RSI49.92
Earnings DateAug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange Brazil Stock Exchange
Ticker Symbol LILY34
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.